课件：恶性淋巴瘤ppt.ppt

JCO, 10:378-382, 1992 Eur J Cancer, 11:1853-1855, 1992 JCO, 10:378-382, 1992 Eur J Cancer, 11:1853-1855, 1992 Specht L, et al. JCO, 16:830-843, 1998 Specht L, et al. JCO, 16:830-843, 1998 1. MilanA. 3 ABVD + EF 116 FFS (7-y) 80.8%, OS 77.4% 1987B. 3 MOPP+EF+3 MOPP 91 DFS (7-y) 62.8%, OS 67.9% 3. EORTCA. 8 MOPP FFS (6-y) 43% 1994B. 8 MOPP/ABVD FFS (6-y) 60% Conellos GP, NEJM, 327, 1478-1484, 1992 Somers R, et al. JCO, 12:279-287, 1994 Level I Evidence Level I Evidence Level I Evidence Hasenclever D, NEJM, 339, 1506-1514, 1998 B-CLL/SLL Harris NL, Ann Oncol, 1997;8:S11 Harris NL, Ann Oncol, 1997;8:S11 NHL Project, Blood 1997;89:3909 Miller TP et al, NEJM 1998;339:21 Clinical Variable 8 Cycles of CHOP (N=201) 3 Cycles of CHOP Plus Radiotherapy (N=200) Stage I 135 (67%) 136 (68%) II 66 (33%) 64 (32%) LDH Normal 159 (79%) 159 (80%) Increased 42 (21%) 41 (20%) Performance0 or 1 193 (96%) 194 (97%) status2 8 (4%) 6 (3%) No of risk 0 or 1 142 (71%) 147 (74%) factors 2 44 (22%) 38 (19%) 3 14 (7%) 14 (7%) 4 1 (1%) 1 (1%) (N=225) (218) (223) CytaBOM(233) P CHOP MACOP-B m-BACOD ProMACE- DupontC-MOPP28 (3-y)31 (36 m) BACOP 4849 HagbergCHOP-35 (36 m) 0.05 MEV -30 CooperCHOP-45 (30 m) MACOP-B -63 TuraF-MACHOP84 (28 m)84 (32 m) MACOP-B 8064 Gherlinzonim-BACOD60 (58 m)57 (58 m) m-BNCOD 5552 Smalley, et al, NEJM, 1992;327:1336 Risk Group